Perinatal Substance Use Is Rising Alongside Maternal and Infant Risk
Perinatal substance use has become a persistent clinical problem across pregnancy and the postpartum period, with implications that extend from maternal mental health to neonatal outcomes. Opioids, alcohol, cannabis, stimulants, and other substances can all complicate pregnancy in different ways, but the common thread is clear: ongoing exposure during gestation raises the likelihood of preterm birth, low birth weight, neonatal abstinence syndrome, and broader medical and psychosocial instability.
The clinical reality is more nuanced than a simple yes-or-no exposure history. Many women reduce or stop substance use once pregnancy is recognized, which means the pregnant population is heterogeneous and screening has to distinguish occasional use from substance use disorder. Women who continue using during pregnancy are more likely to meet criteria for a substance use disorder and often need coordinated care rather than brief advice alone.
Racial and ethnic disparities also shape the burden of harm. White women have the highest prevalence of drug use during the postpartum period, while Black women appear to face a greater risk of adverse consequences tied to substance use during pregnancy and after delivery. Those differences point to a care environment in which access, trust, surveillance, and punishment can matter as much as the exposure itself.
Universal Screening Works Only When It Is Nonjudgmental
Early identification is central to better obstetric and neonatal outcomes. Universal screening at the first prenatal visit is the standard approach, and it should be conducted for every patient regardless of race, ethnicity, or socioeconomic status. Screening loses clinical value when it becomes selective, punitive, or framed as a tool for surveillance rather than care.
The practical tools are already established. The NIDA Quick Screen/ASSIST begins with a brief screen and moves to a more detailed assessment when needed. The 4 P’s Plus is specifically designed for use in pregnancy, and the SURP-P is a three-question scale that helps differentiate lower- from higher-risk populations. Each relies on direct questioning about current and past use, associated harms, and the ways substance use affects daily functioning.
A biologic screen can sometimes add information, but urine or blood toxicology should only be used with informed consent and never as punishment. Punitive policies drive patients away from prenatal care and do not improve birth outcomes. A person-centered approach, in contrast, increases the odds that women will disclose use honestly and return for follow-up when it matters most.
Alcohol, Cannabis, Opioids, and Stimulants Do Not Carry the Same Risks
Alcohol exposure in pregnancy remains especially concerning because there is no known safe amount. Fetal Alcohol Spectrum Disorders can produce lifelong physical, behavioral, and learning problems, and risk rises with heavier use or binge drinking. Even so, the message is not limited to women who quit early in pregnancy: stopping at any point can still benefit the fetus.
When alcohol use disorder is present, brief counseling may help some patients, while others need referral to specialized treatment. In selected cases, medication-assisted management of withdrawal symptoms may be required under close supervision. The underlying clinical principle is straightforward—withdrawal, intoxication, and relapse all place both mother and fetus at risk, so treatment has to be medically managed rather than improvised.
Cannabis use has increased among women of childbearing age, especially in places where legalization has normalized access. In pregnancy, tetrahydrocannabinol crosses the placenta and can interfere with fetal brain development. Associated outcomes include lower birth weight, preterm birth, higher rates of neonatal intensive care admission, and potential long-term effects on cognition and behavior.
The mechanism is biologically plausible even without overstatement: an exogenous psychoactive compound entering the fetal environment during organogenesis and brain development can alter developmental trajectories. Pregnant patients who use cannabis for nausea, anxiety, or other symptoms need safer alternatives, not dismissive counseling.
Opioids present a different but equally urgent challenge. Most opioid use in pregnancy is prescription-based, and a substantial proportion of women who used opioids during pregnancy obtained them from a healthcare provider. Misuse remains common, and untreated opioid use disorder is associated with poor fetal growth, preterm birth, stillbirth, and neonatal abstinence syndrome.
For opioid use disorder, methadone and buprenorphine remain the standard of care. These medications stabilize opioid levels, reduce withdrawal symptoms, improve prenatal care adherence, and lower relapse risk. Abrupt discontinuation is dangerous because maternal withdrawal can harm the fetus; medically supervised treatment is the safer path.
Stimulants such as cocaine and methamphetamine can also cross the placenta and disrupt pregnancy. Placental abruption, preterm labor, and intrauterine growth restriction are among the recognized risks. Unlike opioid use disorder, there are no approved medication-assisted treatments for stimulant use disorders in pregnancy, so care generally relies on behavioral interventions such as cognitive-behavioral therapy and contingency management.
Postpartum Relapse Risk Is High and Requires Active Follow-Up
The postpartum period is not a low-risk interval. Sleep deprivation, pain after delivery, anxiety, depression, childcare stress, and reduced monitoring all increase vulnerability to relapse. Drug-related deaths, including intentional and unintentional overdose, have become a leading cause of death among postpartum women, especially in the 6-12 months after birth.
That risk makes follow-up after delivery a medical necessity, not an optional add-on.
Breastfeeding deserves individualized counseling rather than blanket advice. It is generally encouraged because of its benefits for mother and infant, but safety depends on the substance involved, the likelihood of infant exposure, and the mother’s ability to provide safe care. The conversation has to be clinically specific, not ideological.
Integrated Care Improves the Odds of Recovery
The strongest support models combine prenatal care, mental health treatment, substance use treatment, and parenting support in one system. Peer support from recovery coaches or mentors with lived experience can reduce isolation and improve engagement. Trauma-informed care is essential because many women with substance use disorders have histories of trauma, and insensitive encounters can intensify avoidance and mistrust.
Recovery is also shaped by social determinants of health. Housing, transportation, childcare, and legal stressors can determine whether a woman is able to attend treatment or refill medication. Family-centered care, when appropriate, can add stability, while continued postpartum support helps prevent the abrupt drop-off in care that often follows delivery.
Programs such as EMPOWER, which coordinate early referrals, peer support, doula services, and treatment access, illustrate how multidisciplinary care can be organized around the needs of pregnant and postpartum women. The model is practical: reduce barriers, maintain continuity, and keep treatment active across the perinatal window.
Recovery Cannot Stop at Delivery
Perinatal substance use is not solved by a positive screen or a single counseling session. The clinical burden spans obstetrics, psychiatry, pediatrics, addiction medicine, and social care, and the highest-yield interventions begin with universal screening, then move quickly to individualized treatment and sustained postpartum follow-up.
What remains unresolved is not the need for care, but the system’s willingness to deliver it without stigma, delay, or punishment. Women do better when treatment is accessible, coordinated, and compassionate, and infants benefit when maternal recovery is treated as part of the same clinical mission.